HCC depends on activation of pathways involving tyrosine kinase receptors (TKR), including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and hepatocyte growth factor (HGF)/c-mesenchymal-epithelial transition factor (c-Met), to activate Ras/Raf/mitogen-activated protein Kinases (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signalling pathways that are important for proliferation, survival and angiogenesis [5]. Here, MET is linked to hepatocellular carcinoma.